Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  AMAG Pharmaceuticals, Inc.    AMAG

AMAG PHARMACEUTICALS, INC.

(AMAG)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Global Stem Cell (Cord Blood Banking) Market Value Expected To Grow To $10.79 B By 2022

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/01/2019 | 01:06pm EST

AMAG Pharmaceuticals Is One Of The Largest Companies In The Stem Cell/Cord Blood Banking Market, According To TBRC's Report (Companies: AMAG Pharmaceuticals, Cordlife, Cryo-Cell International, Esperite, and Americord Registry LLC)

The global stem cell/cord blood banking market was valued at about $6 billion in 2018.

The stem cell/cord blood banking global market consists of sales of stem cell/cord blood banking services and related goods. Cord stem cells are referred to as regenerative medicines that help in the regeneration of tissues or cells in the body. Stem cell therapy is designed to aid the physician in performing medical treatment of different types of cancers, neurodegenerative diseases, graft-versus-host disease, and heart diseases.

Read More On The Global Stem Cell/Cord Blood Banking Market Report At:

https://www.thebusinessresearchcompany.com/report/stem-cell-chord-blood-banking-global-market-report

The global stem cell/cord blood banking market is expected to grow to about $10 billion at a growth rate of about 11% through 2022. An increasing number of cancer patients is a major driver for the stem cell/cord blood banking market. Cancer diseases such as leukemia and multiple myeloma can be treated by stem cell transplant. By using stem cells in the treatment of cancer, the blood-forming stem cells which are damaged during chemotherapy can be restored. According to the National Cancer Institute, in 2018, around 609,640 deaths were caused due to prevalence of cancer which can be treated by transplanting the stem cells.

Lack of awareness especially among pregnant women is a major restraint for the stem cell/cord blood banking market. This is mainly because a majority of pregnant women are unaware of the functioning of the public cord blood banks.

The pairing of cord blood and tissue storage with genetic testing services is an emerging trend in the stem cell/cord blood banking market. Such pairing is possible and efficient because of its complimentary services to the existing clients, thereby helping in expanding their product portfolio.

Major players in the market are AMAG Pharmaceuticals, Cordlife, Cryo-Cell International, Esperite, and Americord Registry LLC.

AMAG Pharmaceuticals, Inc. is an American pharmaceutical company developing products that treat iron deficiency anemia (IDA) in adult patients. The company is a publicly-traded company listed on NASDAQ under the symbol "AMAG".

Request A Sample Of The Global Stem Cell/Cord Blood Banking Market Report At:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2514&type=smp.

Points from Table of Contents:

4. Stem Cell Cord Blood Banking Market Segmentation

4.1. Global Stem Cell Cord Blood Banking Market, Segmentation By Cell Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Adult Stem Cells

Umbilical Cord Blood Stem Cells

Embryonic Stem Cells

4.2. Global Stem Cell Cord Blood Banking Market, Segmentation By Service, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Collection

Processing

Analysis

Storage

4.3. Global Stem Cell Cord Blood Banking Market, Segmentation By Bank Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Public

Private

4.4. Global Stem Cell Cord Blood Banking Market, Segmentation By Application, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Leukemia

Anemia

Thalassemia

Autism

Cerebral palsy

Diabetes

Others

5. Stem Cell Cord Blood Banking Market Regional And Country Analysis

5.1. Global Stem Cell Cord Blood Banking Market, Split By Region, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

5.2. Global Stem Cell Cord Blood Banking Market, Split By Country, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

6. Asia-Pacific Stem Cell Cord Blood Banking Market

6.1. Asia-Pacific Stem Cell Cord Blood Banking Market Overview

6.2. Asia-Pacific Stem Cell Cord Blood Banking Market, Segmentation By Cell Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

Order a copy of complete report @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2514

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company

Media Contact

Company Name: The Business Research Company

Contact Person: Nitin

Email: marketing@tbrc.info

Phone: 08897263534

Address:1st Floor, Anshu Colors Building, Road Number 1 Park View Enclave, Jubilee Hills

City: Hyderabad 500033

State: Telengana

Country: India

Website: https://www.thebusinessresearchcompany.com/report/stem-cell-cord-blood-banking-global-market-report

Source: www.abnewswire.com

.

(C) 2019 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
AMAG PHARMACEUTICALS, INC. 0.00% 9.86 Delayed Quote.-35.09%
CORDLIFE GROUP LIMITED -4.08% 0.47 End-of-day quote.27.03%
CRYO-CELL INTERNATIONAL, INC. -0.51% 7.86 Delayed Quote.4.80%
ESPERITE -3.22% 0.0511 Delayed Quote.-55.93%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMAG PHARMACEUTICALS, INC.
11/13AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
GL
11/04AMAG PHARMACEUTICALS : Announces third quarter 2019 financial results and provid..
AQ
11/01AMAG PHARMACEUTICALS : Makena® (hydroxyprogesterone caproate injection) Approval..
PU
11/01AMAG PHARMACEUTICALS, INC. MANAGEME : (form 10-Q)
AQ
11/01AMAG PHARMACEUTICALS : Announces third quarter 2019 financial results and provid..
PU
11/01AMAG PHARMACEUTICALS : 3Q Earnings Snapshot
AQ
11/01AMAG PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Fina..
AQ
11/01AMAG Pharmaceuticals Announces Third Quarter 2019 Financial Results and Provi..
GL
10/30AMAG PHARMACEUTICALS : Stock Trading Halted Today FDA Advisory Committee Meeting..
AQ
10/30AMAG PHARMACEUTICALS : Reports on fda advisory committee meeting for makena
AQ
More news
Financials (USD)
Sales 2019 327 M
EBIT 2019 -270 M
Net income 2019 -288 M
Debt 2019 92,9 M
Yield 2019 -
P/E ratio 2019 -1,16x
P/E ratio 2020 -3,64x
EV / Sales2019 1,31x
EV / Sales2020 1,36x
Capitalization 334 M
Chart AMAG PHARMACEUTICALS, INC.
Duration : Period :
AMAG Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMAG PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 11,22  $
Last Close Price 9,86  $
Spread / Highest target 62,3%
Spread / Average Target 13,8%
Spread / Lowest Target -39,1%
EPS Revisions
Managers
NameTitle
William K. Heiden President, Chief Executive Officer & Director
Gino Santini Chairman
Edward H. Myles Chief Financial Officer, Treasurer & EVP
Julie Krop Chief Medical Officer & Executive Vice President
Brian Robinson Senior Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
AMAG PHARMACEUTICALS, INC.-35.09%334
JOHNSON & JOHNSON4.56%355 145
ROCHE HOLDING AG20.79%255 382
MERCK AND COMPANY11.11%216 154
PFIZER-14.59%206 312
NOVARTIS18.75%202 726